Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 51INDUSTRY 15NIH 9NETWORK 3UNKNOWN 1OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 36Stomach Neoplasms 19Esophageal Neoplasms 17Carcinoma, Non-Small-Cell Lung 13Colorectal Neoplasms 12Rectal Neoplasms 11Triple Negative Breast Neoplasms 9Brain Neoplasms 8Small Cell Lung Carcinoma 7Lung Neoplasms 7Squamous Cell Carcinoma of Head and Neck 6Neoplasms 6Neoplasm Metastasis 6Esophageal Squamous Cell Carcinoma 6Nasopharyngeal Carcinoma 4Melanoma 4Lymphoma, Extranodal NK-T-Cell 4Carcinoma, Hepatocellular 4Uterine Cervical Neoplasms 3Recurrence 3Meningeal Carcinomatosis 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma 3Leukemia, Myeloid, Acute 3Head and Neck Neoplasms 3Colonic Neoplasms 3Vomiting 2Urinary Bladder Neoplasms 2Skin Diseases 2Sarcoma 2

Interventions

Thalidomide 1Temozolomide 1Tegafur 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
UNKNOWN × Interventional × Adenoma, Islet Cell × Clear all
NCT03204019 2017-06-29

A Study of Tegafur Combined With Temozolomide Versus Tegafur Combined With Temozolomide and Thalidomide in Subjects With Advanced Pancreatic Neuroendocrine Tumor

ChineseAMS

Phase 2 Unknown
60 enrolled

Adenoma, Islet Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡